V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 11.9 DKK -1.65% Market Closed
Market Cap: 92.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ViroGates A/S
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Cash Equivalents
kr7.4m
CAGR 3-Years
-25%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Cash Equivalents
kr1.1B
CAGR 3-Years
-12%
CAGR 5-Years
18%
CAGR 10-Years
24%
Ambu A/S
CSE:AMBU B
Cash Equivalents
kr350m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ViroGates A/S
Glance View

Market Cap
92.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.15 DKK
Overvaluation 73%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Cash Equivalents?
Cash Equivalents
7.4m DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Cash Equivalents amounts to 7.4m DKK.

What is ViroGates A/S's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-31%

Over the last year, the Cash Equivalents growth was 16%. The average annual Cash Equivalents growth rates for ViroGates A/S have been -25% over the past three years , -31% over the past five years .

Back to Top